Adcentrx Therapeutics bags $38m to take ADC oncology pipeline to clinical trials

The US-Chinese company Adcentrx Therapeutics has raised $38m in a Series A+ round to begin a phase 1 trial of its lead candidate antibody-drug conjugate (ADC) later this year.

Related Keywords

Hui Li ,Trinity Innovation Fund ,Eight Roads Ventures ,F Prime Capital ,Delta Capital ,Trinity Innovation ,Bio Developments ,Pipelines ,Antibody Drug Conjugates ,Dc ,Antibody Drug Conjugate ,Dancer ,Ncology ,